4-iodo-1H-benzotriazole | 116975-12-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并三唑类
• 英文名称: 4-iodo-1H-benzotriazole
• 英文别名: 4-Jod-1H-benzotriazol；4-Iodo-1H-benzo[d][1,2,3]triazole；4-iodo-2H-benzotriazole
• CAS: 116975-12-3
• 化学式: C₆H₄IN₃
• 分子量: 245.022
• InChiKey: PGAXPOCPKLMZIW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-硝基-1H-1,2,3-苯并三唑 在 盐酸 、 tin(ll) chloride 、 sodium nitrite 作用下， 生成 4-iodo-1H-benzotriazole
  参考文献：
  名称：

  Wiley; Hussung, Journal of the American Chemical Society, 1957, vol. 79, p. 4395,4399

  摘要：

  DOI：

文献信息

• [EN] COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY<br/>[FR] COMPOSÉS INHIBANT L'ACTIVITÉ ENZYMATIQUE DE LA KINASE À RÉPÉTITIONS RICHES EN LEUCINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2015026683A1

  公开（公告）日：2015-02-26

  The present invention is directed to azaindazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

  本发明涉及氮杂吲哚化合物，这些化合物是LRRK2激酶的有效抑制剂，并且在治疗或预防LRRK2激酶参与的疾病，如帕金森病中有用。该发明还涉及包含这些化合物的药物组合物，以及在预防或治疗LRRK2激酶参与的疾病中使用这些化合物和组合物。
• COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY
  申请人：DEMONG Duane

  公开号：US20160200722A1

  公开（公告）日：2016-07-14

  The present invention is directed to azaindazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

  本发明涉及一种阿扎印唑化合物，其是LRRK2激酶的有效抑制剂，可用于治疗或预防LRRK2激酶参与的疾病，如帕金森病。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗LRRK-2激酶参与的疾病中使用这些化合物和组合物。
• NONAQUEOUS ELECTROLYTE AND NONAQUEOUS SECONDARY BATTERY
  申请人：Asahi Kasei Kabushiki Kaisha

  公开号：EP3279997A1

  公开（公告）日：2018-02-07

  The purpose of the present invention is to provide a nonaqueous electrolyte that contains acetonitrile having an excellent balance between viscosity and the dielectric constant and a fluorine-containing inorganic lithium salt, wherein the generation of complex cations comprising a transition metal and acetonitrile is suppressed, excellent load characteristics are exhibited, and increases in internal resistance upon repeated charge/discharge cycles are suppressed; a further purpose of the present invention is to provide a nonaqueous secondary battery. The present invention relates to a nonaqueous electrolyte which contains: a nonaqueous solvent comprising acetonitrile; a fluorine-containing inorganic lithium salt; and a specific nitrogenous cyclic compound typified by benzotriazole.

  本发明的目的是提供一种非水电解液，该电解液含有在粘度和介电常数之间具有极佳平衡的乙腈和含氟无机锂盐，其中包含过渡金属和乙腈的复合阳离子的生成受到抑制，显示出极佳的负载特性，并且在重复充放电循环中内阻的增加受到抑制；本发明的另一个目的是提供一种非水二次电池。本发明涉及一种非水电解液，其中包含：由乙腈组成的非水溶剂；含氟无机锂盐；以及以苯并三唑为典型代表的特定含氮环状化合物。
• TETRAHYDROPYRROLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF
  申请人：Mediconns (Shanghai) Biopharmaceutical Co., Ltd

  公开号：EP3733670A1

  公开（公告）日：2020-11-04

  The present invention discloses a tetrahydropyrrole compound, a preparation method therefor, a pharmaceutical composition containing the same, and a use thereof. The tetrahydropyrrole compound of the present invention is represented by general formula (I). The tetrahydropyrrole compound of the present invention has better inhibitory effects on the positive symptoms of schizophrenia, and the potency thereof is equivalent to or slightly stronger than that of the positive drug olanzapine. In addition, the compound of the present invention has dual inhibitory effects on D2 receptors and DAT receptors, and is effective for treating schizophrenia and improving negative symptoms and cognitive functions, while also reducing vertebral side effects and prolactin secretion.

  本发明公开了一种四氢吡咯化合物、其制备方法、含有该化合物的药物组合物及其用途。本发明的四氢吡咯化合物由通式（I）表示。本发明的四氢吡咯化合物对精神分裂症阳性症状有较好的抑制作用，其药效与阳性药物奥氮平相当或稍强于奥氮平。此外，本发明化合物对D2受体和DAT受体具有双重抑制作用，能有效治疗精神分裂症，改善阴性症状和认知功能，同时还能减少椎体副作用和催乳素分泌。
• [EN] BENZENE RING-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF<br/>[FR] COMPOSÉ CONTENANT UN CYCLE BENZÉNIQUE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION<br/>[ZH] 含苯环的化合物、其制备方法及应用
  申请人：GUANGZHOU WELLHEALTH BIO PHARMACEUTICAL CO LTD

  公开号：WO2020011246A1

  公开（公告）日：2020-01-16

  一种含苯环的化合物、其制备方法及应用。具体提供了一种如式（I-0）所示化合物、其药学上可接受的盐、其溶剂合物、其代谢产物、其立体异构体、其互变异构体或其前药。该化合物可用作免疫调节剂，其呈现活性高、药效好、药物稳定、以及可与其它免疫调节剂进行联合用药等优点。